Skip to content
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Sigyn Therapeutics, Inc. SIGY

10 fiscal years on record · USD · FY2024 reported · SEC filings only
$-3.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Sigyn Therapeutics, Inc. develops medical devices to treat cancer and infectious disease disorders. The company believes its lineup of therapeutic candidates is among the most expansive in the field of extracorporeal blood purification. To optimize the benefit of drugs to treat cancer, it invented the ImmunePrep platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep to improve the delivery of chemotherapy, and ChemoPure to reduce chemotherapy toxicity. Its lead therapeutic candidate is Sigyn Therapy, aimed at infectious disease disorders that are not treatable with drugs. To address infectious disease disorders that are not treatable with drugs, the company designed Sigyn Therapy to extract deadly pathogens and toxins from a patient's bloodstream, while simultaneously providing a mechanism to dampen down excessive immune responses that are associated with life-threatening infections. Its therapeutic candidates include the ImmunePrep platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep to improve the delivery of chemotherapy, and ChemoPure to extract off-target chemotherapy from the bloodstream to reduce treatment toxicity.

Written from the business description in Sigyn Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2025. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2024 · full 10-year series below
Revenue $M Net income $M
FY2019 · Revenue 0.1 · Net income -3.1
-2M-3M
2014201820212024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2019 · Operating -361.4%
-2000%-4000%-6000%
201420192024
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -1.8
-1M-2M
201420192024

Total assetsUSD 213,719.00
EquityUSD -4.5M
CashUSD 12,144.00
Gross debtUSD 2.2M
Net debtUSD 2.2M
Current ratio0.00×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SIGY, 10-year financial record
Metric 2024202320222021202020192018201720152014
Revenue $B◌◌◌◌◌0.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B◌◌◌◌◌◌0.00.0◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0◌◌−0.0−0.0−0.0−0.0
EPS, diluted $−2.51−3.77−3.13−0.08−0.17−0.04−0.04−0.09−0.09−0.01
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %—————————−389.8
Shares out B0.000.000.040.040.040.000.080.050.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Seven checks were skipped: EPS is not tagged before 2014. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image